LivaNova Makes Significant Changes to BoardLivaNova Makes Significant Changes to Board

The changes on the board come after the London-based company decided to sell its heart valve business to Gyrus Capital for $73 million.

Omar Ford

December 7, 2020

2 Min Read
IMG_Dec72020at123724PM.jpg
hd3dsh -stock.adobe.com

LivaNova isn’t finished with its big changes yet. The London-based company is now making what it calls “a series of enhancements” to its governance.

Former C.R. Bard CFO, Todd Schermerhorn joins the board and Hugh Morrison is set to retire from the board after five years of service. Moore will rotate from the role of Board Chair, effective as of the Annual General Meeting of Shareholders in 2021 (2021 AGM).

Moore will remain a director. William Kozy, who currently serves on the Nominating and Corporate Governance Committee, will succeed Moore as Chair at that time. Kozy joined the LivaNova Board in 2018 and also serves on the Board of Cooper Companies.

In addition, LivaNova announced that Dr. Arthur L. Rosenthal will rotate from the role of Chair of the Compensation Committee, following the 2021 AGM. Rosenthal will remain a Director. Stacy Enxing Seng, who currently serves on the Compensation Committee, will assume the Chair role at that time. Enxing Seng joined the Board in 2019 and is also a Director of Sonova Holding AG and Hillrom Holdings.

"The actions we announced today were driven by our Nominating and Corporate Governance Committee and underscore our commitment to leading corporate governance and helping to further enhance the board's independent oversight,” Daniel Moore, LivaNova’s board chair said in a release.

LivaNova has been going through some significant changes recently and can arguably be traced back to an open letter from an active investor PrimeStone Capital. The letter urged LivaNova to refocus its capital on the neuromodulation business, divest its cardiopulmonary business, and either sell or close its heart valves business. The investor recommended that the board appoint a new chairman and hire a new CFO.

A little more than a month after the letter, LivaNova followed up on some of PrimeStone Capital’s recommendations and sold the heart valve business to Gyrus Capital for $73 million.

Shortly after PrimeStone’s letter, LivaNova’s CFO Thad Huston resigned.

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like